317 related articles for article (PubMed ID: 8289372)
1. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
Morrison LA; Knipe DM
J Virol; 1994 Feb; 68(2):689-96. PubMed ID: 8289372
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.
Morrison LA; Knipe DM
Virology; 1996 Jun; 220(2):402-13. PubMed ID: 8661391
[TBL] [Abstract][Full Text] [Related]
4. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.
Keadle TL; Morrison LA; Morris JL; Pepose JS; Stuart PM
J Virol; 2002 Apr; 76(8):3615-25. PubMed ID: 11907201
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunization on herpes simplex virus type 1 latent infection in the trigeminal ganglion.
Kramer M; Riley J; Spoering A; Coen D; Knipe D
Curr Eye Res; 2003; 26(3-4):185-94. PubMed ID: 12815546
[TBL] [Abstract][Full Text] [Related]
7. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
Osorio Y; Ghiasi H
J Virol; 2005 Mar; 79(6):3297-308. PubMed ID: 15731224
[TBL] [Abstract][Full Text] [Related]
8. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
Augustinova H; Hoeller D; Yao F
J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
van Lint AL; Torres-Lopez E; Knipe DM
Virology; 2007 Nov; 368(2):227-31. PubMed ID: 17915278
[TBL] [Abstract][Full Text] [Related]
10. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.
Matundan H; Mott KR; Ghiasi H
J Virol; 2014 Jul; 88(14):8016-27. PubMed ID: 24807710
[TBL] [Abstract][Full Text] [Related]
11. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
Geiss BJ; Smith TJ; Leib DA; Morrison LA
J Virol; 2000 Dec; 74(23):11137-44. PubMed ID: 11070010
[TBL] [Abstract][Full Text] [Related]
12. Herpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the Lip.
Poccardi N; Rousseau A; Haigh O; Takissian J; Naas T; Deback C; Trouillaud L; Issa M; Roubille S; Juillard F; Efstathiou S; Lomonte P; Labetoulle M
J Virol; 2019 Dec; 93(24):. PubMed ID: 31554680
[TBL] [Abstract][Full Text] [Related]
13. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
Osorio Y; Ghiasi H
J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
[TBL] [Abstract][Full Text] [Related]
14. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
Lu Z; Brans R; Akhrameyeva NV; Murakami N; Xu X; Yao F
J Invest Dermatol; 2009 May; 129(5):1174-84. PubMed ID: 19005489
[TBL] [Abstract][Full Text] [Related]
15. Maternal immunization with a herpes simplex virus type 2 replication-defective virus reduces visceral dissemination but not lethal encephalitis in newborn mice after oral challenge.
Evans IA; Jones CA
J Infect Dis; 2002 Jun; 185(11):1550-60. PubMed ID: 12023760
[TBL] [Abstract][Full Text] [Related]
16. An M2 Rather than a T
Lee DH; Ghiasi H
J Virol; 2018 May; 92(10):. PubMed ID: 29491152
[TBL] [Abstract][Full Text] [Related]
17. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
Morrison LA; Zhu L; Thebeau LG
J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.
Brehm MA; Bonneau RH; Knipe DM; Tevethia SS
J Virol; 1997 May; 71(5):3534-44. PubMed ID: 9094625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
